TrGET: Preclinical Assay Platform
Yves Collette (Scientific Director)+33 (0)220.127.116.11.31
Remy Castellano (Technical Manager) +33(0)18.104.22.168.32
TrGET (created in 2007) offers cell-based assay platforms and proof-of-concept in vivo studies for preclinical evaluation of therapeutic/pharmacological target candidates and therapeutic strategies in oncology.
A variety of flexible and customizable services is available, with privileged technological developments of bioluminescence-based technologies allowing quantitative evaluation of cell viability, proliferation, apoptosis, clonogenicity and migration in vitro, as well as tumoral progression and metastatic development in vivo.
Optimization of therapeutic strategies is proposed through the combination of investigated active molecules with sets of known therapeutics/targeted drug inhibitors and quantitive evaluation of synergism. Chemo-proteomic profiling is also offered to facilitate the evaluation of drug specificity and mechanism of action.
The platform works in close collaboration with ETOH (Evaluation of Therapeutic Onco-Hematology) IPC unit dedicated exclusively to early clinical trials to accelerate the evaluation of innovative therapeutic approaches (labeled by the ARS and granted by INCa in 2010).
This unique combination of preclinical and clinical services provide the tools to address the scientific challenges encountered during any stage of product development.
These activities relies on and/or are linked to strongly established IPC/CRCM facilties, including the following:
- - Animal facility which provides the basic animal breeding and maintenance service in the Specific and Opportunistic Pathogen Free (SOPF) areas with individually ventilated caging systems
- - BioBank (IBiSA)
- - Marseille Proteomic Platform (IBiSA)
- - Immunomonitoring Platform (IBiSA)
TrGET was granted by the Cancéropôle PACA, the PROCAN program, the Région PACA, and is supported by academic granted partneship from INCa, ARC, Ligue contre le cancer, as well as by contracting with Biotech compagnies (SERVIER-ONCO, U3-Pharma, Nanova, ValiRX) and development unit (INSERM-Transfert, Valor-PACA).
- Drug response profiling can predict response to ponatinib in a patient with t(1;9)(q24;q34)-associated B-cell acute lymphoblastic leukemia. Collette Y, Prébet T, Goubard A, Adélaïde J, Castellano R, Carbuccia N, Garnier S, Guille A, Arnoulet C, Charbonier A, Mozziconacci MJ, Birnbaum D, Chaffanet M, Vey N. Blood Cancer J. 2015 Mar 13;5. Pubmed ID: 25768406
- A robust and rapid xenograft model to assess efficacy of chemotherapeutic agents for human acute myeloid leukemia. Saland E, Boutzen H, Castellano R, Pouyet L, Griessinger E, Larrue C, de Toni F, Scotland S, David M, Danet-Desnoyers G, Vergez F, Barreira Y, Collette Y, Récher C, Sarry JE. Blood Cancer J. 2015 Mar 20;5. Pubmed ID: 25794133
- Therapeutic targeting of c-Myc in T-cell acute lymphoblastic leukemia, T-ALL. Loosveld M, Castellano R, Gon S, Goubard A, Crouzet T, Pouyet L, Prebet T, Vey N, Nadel B, Collette Y, Payet-Bornet D. Oncotarget. 2014 May 30;5(10):3168-72. Pubmed ID: 24930440
- CD95L cell surface cleavage triggers a prometastatic signaling pathway in triple-negative breast cancer. Malleter M, Tauzin S, Bessede A, Castellano R, Goubard A, Godey F, Levêque J, Jézéquel P, Campion L, Campone M, Ducret T, MacGrogan G, Debure L, Collette Y, Vacher P, Legembre P. Cancer Res. 2013 Nov 15;73(22):6711-21. Pubmed ID: 24072745
- Human Vγ9Vδ2 T cells specifically recognize and kill acute myeloid leukemic blasts. Gertner-Dardenne J, Castellano R, Mamessier E, Garbit S, Kochbati E, Etienne A, Charbonnier A, Collette Y, Vey N, Olive D. J Immunol. 2012 May 1;188(9):4701-8. Pubmed ID: 22467661
- Primary B-CLL Resistance to NK Cell Cytotoxicity can be Overcome In Vitro and In Vivo by Priming NK Cells and Monoclonal Antibody Therapy. Veuillen C, Aurran-Schleinitz T, Castellano R, Rey J, Mallet F, Orlanducci F, Pouyet L, Just-Landi S, Coso D, Ivanov V, Carcopino X, Bouabdallah R, Collette Y, Fauriat C, Olive D. J Clin Immunol. 2012 Feb 9. Pubmed ID: 22318393
- Human breast tumor cells induce self-tolerance mechanisms to avoid NKG2D-mediated and DNAM-mediated NK cell recognition. Mamessier E, Sylvain A, Bertucci F, Castellano R, Finetti P, Houvenaeghel G, Charaffe-Jaufret E, Birnbaum D, Moretta A, Olive D. Cancer Res. 2011 Nov 1;71(21):6621-32. Pubmed ID: 21937679
- Human breast cancer cells enhance self tolerance by promoting evasion from NK cell antitumor immunity. Mamessier E, Sylvain A, Thibult ML, Houvenaeghel G, Jacquemier J, Castellano R, Gonçalves A, André P, Romagné F, Thibault G, Viens P, Birnbaum D, Bertucci F, Moretta A, Olive D. J Clin Invest. 2011 Sep;121(9):3609-22. doi: 10.1172/JCI45816. Pubmed ID: 21841316
- Anti-leukemia activity of chaetocin via death receptor-dependent apoptosis and dual modulation of the histone methyl-transferase SUV39H1. Chaib H, Nebbioso A, Prebet T, Castellano R, Garbit S, Restouin A, Vey N, Altucci L, Collette Y. Leukemia. 2011 Oct 7. Pubmed ID: 21979880
- Loss of AF6/afadin, a marker of poor outcome in breast cancer, induces cell migration, invasiveness and tumor growth. Fournier G, Cabaud O, Josselin E, Chaix A, Adélaïde J, Isnardon D, Restouin A, Castellano R, Dubreuil P, Chaffanet M, Birnbaum D, Lopez M. Oncogene. 2011 Sep 8;30(36):3862-74. doi: 10.1038/onc.2011.106. Epub 2011 Apr 11. Pubmed ID: 21478912
- Modified cap group suberoylanilide hydroxamic acid histone deacetylase inhibitor derivatives reveal improved selective antileukemic activity. Salmi-Smail C, Fabre A, Dequiedt F, Restouin A, Castellano R, Garbit S, Roche P, Morelli X, Brunel JM, Collette Y. J Med Chem. 2010 Apr 22;53(8):3038-47.Pubmed ID: 20218673
- Regulation of insulin-like growth factor-mammalian target of rapamycin signaling by microRNA in childhood adrenocortical tumors. Doghman M, El Wakil A, Cardinaud B, Thomas E, Wang J, Zhao W, Peralta-Del Valle MH, Figueiredo BC, Zambetti GP, Lalli E. Cancer Res. 2010 Jun 1;70(11):4666-75. Pubmed ID: 2048403
- A simplified, 96-well-adapted, ATP luminescence-based motility assay. Restouin A, Aresta S, Prébet T, Borg JP, Badache A, Collette Y. Biotechniques. 2009 Oct;47(4):871-5.Pubmed ID: 19852771
- Amine-guanidine switch: a promising approach to improve DNA binding and antiproliferative activities. Ohara K, Smietana M, Restouin A, Mollard S, Borg JP, Collette Y, Vasseur JJ. J Med Chem. 2007 Dec 27;50(26):6465-75.Pubmed ID: 18052116
- Protein protein interaction inhibition (2P2I) combining high throughput and virtual screening: Application to the HIV-1 Nef protein. Betzi S, Restouin A, Opi S, Arold ST, Parrot I, Guerlesquin F, Morelli X, Collette Y. Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19256-61. Pubmed ID: 18042718
- Yves Collette (DR2 INSERM) 20%
- Remy Castellano (Engineer IPC) 100%
- Audrey Restouin (THQ IPC) 100%
- Emmanuelle Josselin (THQ IPC, CDD) 100%
- Armelle Goubard (THQ IPC, CDD) 100%
- Camille Montersino (IE AMU, CDD) 100%
Cancer Research Center of Marseille (CRCM)
INSERM U 1068 / CNRS UMR 7258
Université Aix-Marseille / Institut Paoli Calmettes
27 Boulevard Leï Roure-BP30059
13 273 Marseille Cedex 09